A Prospective, Randomized, Open, Multi-center Phase III Clinical Study Comparing Efficacy and Safety of Sequential T-FEC and TX-XEC as Post-operative Adjuvant Chemotherapy Options for the Treatment of Triple-negative Breast Cancer

Trial Profile

A Prospective, Randomized, Open, Multi-center Phase III Clinical Study Comparing Efficacy and Safety of Sequential T-FEC and TX-XEC as Post-operative Adjuvant Chemotherapy Options for the Treatment of Triple-negative Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Capecitabine (Primary) ; Capecitabine; Cyclophosphamide; Docetaxel; Epirubicin; Fluorouracil
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Apr 2017 Status changed from recruiting to active, no longer recruiting.
    • 07 Jun 2016 30 months follow-up results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 24 Jul 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top